标题
Assessing Response and Loss of Response to Biological Therapies in IBD
作者
关键词
-
出版物
AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume 106, Issue 4, Pages 685-698
出版商
Springer Nature
发表日期
2011-03-22
DOI
10.1038/ajg.2011.103
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine
- (2010) T. T. MACDONALD et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
- (2010) Gary R. Lichtenstein et al. Clinical Gastroenterology and Hepatology
- Dealing with immunogenicity of biologicals: assessment and clinical relevance
- (2010) Gerrit J Wolbink et al. CURRENT OPINION IN RHEUMATOLOGY
- Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: A Danish single center experience
- (2010) Ane Søgaard Teisner et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Review article: anti TNF-α induced psoriasis in patients with inflammatory bowel disease
- (2009) G. FIORINO et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâs disease after failure of two other anti-TNF antibodies
- (2009) M. ALLEZ et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
- (2009) A Finckh et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
- (2009) Corey A. Siegel et al. Clinical Gastroenterology and Hepatology
- 751f One Year Data from the Sonic Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy
- (2009) William J. Sandborn et al. GASTROENTEROLOGY
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- Adalimumab for the treatment of fistulas in patients with Crohn's disease
- (2009) J-F Colombel et al. GUT
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
- (2009) I. Arijs et al. GUT
- Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohnʼs disease
- (2009) Geert R. DʼHaens et al. INFLAMMATORY BOWEL DISEASES
- Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
- (2009) Klaus Bendtzen et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
- (2009) Andrea Rubbert-Roth et al. ARTHRITIS RESEARCH & THERAPY
- Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease
- (2008) R. L. WEST et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience
- (2008) A. OUSSALAH et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
- (2008) T R D J Radstake et al. ANNALS OF THE RHEUMATIC DISEASES
- Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-α antibodies
- (2008) E. C. Ebert et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
- (2008) Arie E. van der Bijl et al. CLINICAL RHEUMATOLOGY
- 494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study
- (2008) Severine Vermeire et al. GASTROENTEROLOGY
- T1061 Improvement in Short Inflammatory Bowel Disease Questionnaire Scores in Adalimumab-Treated Crohn's Disease Patients Who Failed Infliximab (CHOICE Trial)
- (2008) Simon Lichtiger et al. GASTROENTEROLOGY
- 920 Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease After Infliximab Failure: 1-Year Follow-Up of Gain Trial
- (2008) Remo Panaccione et al. GASTROENTEROLOGY
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
- Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
- (2008) Murat Toruner et al. GASTROENTEROLOGY
- Hepatosplenic T cell lymphoma in inflammatory bowel disease
- (2008) M. Shale et al. GUT
- Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
- (2008) H Fidder et al. GUT
- Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
- (2008) F Schnitzler et al. GUT
- Successful induction of clinical response and remission with certolizumab pegol in Crohnʼs disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use
- (2008) Silvio Danese et al. INFLAMMATORY BOWEL DISEASES
- Emergence of Crohn's Disease During Treatment with the Anti-Tumor Necrosis Factor Agent Etanercept for Ankylosing Spondylitis: Possible Mechanisms of Action
- (2008) Boulos Haraoui et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease
- (2007) Mark A. Ainsworth et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- TNFα blockade in human diseases: Mechanisms and future directions
- (2007) Maida Wong et al. CLINICAL IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started